Scarica l'app Stockscreener
154.17
0.01%
0.010
Dopo l'orario di chiusura:
154.17
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Precedente Chiudi:
$154.16
Aprire:
$153.34
Volume 24 ore:
1.50M
Relative Volume:
1.28
Capitalizzazione di mercato:
$10.68B
Reddito:
$2.71B
Utile/perdita netta:
$247.10M
Rapporto P/E:
44.04
EPS:
3.5008
Flusso di cassa netto:
$349.90M
1 W Prestazione:
-10.05%
1M Prestazione:
-21.71%
6M Prestazione:
-52.75%
1 anno Prestazione:
-50.37%
Intervallo 1D:
$152.13
$155.39
Intervallo di 1 settimana:
$148.31
$170.98
Portata 52W:
$148.31
$354.88
Insulet Corp Stock (PODD) Company Profile
Nome
Insulet Corp
Settore
Industria
Telefono
978-600-7000
Indirizzo
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
154.17 | 10.68B | 2.71B | 247.10M | 349.90M | 3.5008 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Insulet Corp Stock (PODD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| 2026-04-07 | Downgrade | Citigroup | Buy → Neutral |
| 2026-01-27 | Ripresa | TD Cowen | Hold |
| 2026-01-12 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Iniziato | Evercore ISI | Outperform |
| 2025-11-19 | Aggiornamento | UBS | Neutral → Buy |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Ripresa | Oppenheimer | Outperform |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-05-13 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-07 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-07-28 | Iniziato | Wells Fargo | Overweight |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Iniziato | BofA/Merrill | Neutral |
| 2020-03-31 | Downgrade | Berenberg | Buy → Hold |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-10 | Iniziato | CFRA | Sell |
| 2019-10-23 | Iniziato | Stifel | Hold |
| 2019-10-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-10-04 | Downgrade | UBS | Buy → Neutral |
| 2019-10-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-04-20 | Iniziato | Berenberg | Buy |
| 2018-02-22 | Reiterato | Barclays | Overweight |
| 2018-01-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Iniziato | Barclays | Overweight |
Mostra tutto
Insulet Corp Borsa (PODD) Ultime notizie
Benchmark reaffirms Insulet stock rating with $250 price target - Investing.com
Insulet Corp Shs Unsponsored Brazilian Depositary Receipt Repr 0.03333333 Sh - TradingView
This Insulet analyst is no longer bullish; here are top 4 downgrades for Friday - MSN
Insulet Corp. Stock Hits Day Low Amid Price Pressure, Drops to $148.45 - Markets Mojo
Insulet Corp. stock underperforms Wednesday when compared to competitors - MSN
Insulet Corp (PODD) Shares Fall 3.8% -- What GF Score of 83 Tells Investors - GuruFocus
Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch
PODD Maintained by JP Morgan -- Price Target Lowered to $275 - GuruFocus
PODD Reports Strong Q1 Performance with Revenue of $761.7 Millio - GuruFocus
PODD Stock Price, Quote & Chart | INSULET CORP (NASDAQ:PODD) - ChartMill
PODD Maintained by Evercore ISI Group -- Price Target Lowered to $200 - GuruFocus
Evercore ISI Adjusts Price Target on Insulet to $200 From $240 - Moomoo
PODD Maintained by Wells Fargo -- Price Target Lowered to $255 - GuruFocus
PODD Maintained by Oppenheimer -- Price Target Lowered to $210 - GuruFocus
Wells Fargo Lowers Insulet Price Target to $255 From $360 - Moomoo
RBC Capital Adjusts Insulet Price Target to $280 From $325, Maintains Outperform Rating - Moomoo
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Insulet jumps as Q1 results top guidance and full-year outlook rises - Quiver Quantitative
Truist cuts Insulet stock price target to $250 on guidance concerns - Investing.com
Insulet Corporation (NASDAQ:PODD) Q1 2026 Earnings Call Transcript - Insider Monkey
Insulet Corp. Stock Plummets to New 52-Week Low of $148.45 - Markets Mojo
Insulet Corp. Stock Hits Day Low of $158.42 Amid Price Pressure - Markets Mojo
RBC Capital lowers Insulet stock price target on growth concerns - Investing.com
Insulet stock price target lowered to $210 by Oppenheimer on valuation - Investing.com
Bernstein SocGen cuts Insulet stock price target on valuation concerns - Investing.com
Bernstein SocGen cuts Insulet stock price target on valuation concerns By Investing.com - Investing.com Canada
MSN Money - MSN
Insulet Q1 Earnings Call Highlights - Yahoo Finance
Insulet (NASDAQ: PODD) Q1 2026 profit jumps on Omnipod growth - Stock Titan
BTIG cuts Insulet stock price target to $260 on sector multiples - Investing.com
Insulet Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Insulet Reports Record Q1 2026 Results, Raises Full-Year Revenue Guidance on Strong Omnipod Growth - Minichart
Insulet raises revenue expectations for 2026 - MedTech Dive
FMR LLC (PODD) reports 3.96M shares, 5.6% stake in Insulet Corp - Stock Titan
Insulet Q1 2026 slides: 34% revenue growth amid stock decline - Investing.com
Earnings call transcript: Insulet’s Q1 2026 earnings beat expectations, stock dips - Investing.com
Insulet (PODD) Loses 17.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Transcript: Insulet Q1 2026 Earnings Conference Call - Benzinga
Insulet Corp (NASDAQ:PODD) Blows Past Q1 Estimates, Raises Full-Year Revenue Guidance - ChartMill
Insulet (PODD) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Insulet (NASDAQ:PODD) Reports Upbeat Q1 CY2026, Stock Soars - Yahoo Finance
Insulet shares surge 9% on strong earnings beat - Investing.com
Insulet shares surge 9% on strong earnings beat By Investing.com - Investing.com Canada
INSULET ($PODD) Releases Q1 2026 Earnings - Quiver Quantitative
Insulet: Q1 Earnings Snapshot - marketscreener.com
Insulet (NASDAQ: PODD) lifts 2026 outlook after strong Q1 revenue growth - Stock Titan
Insulet Reports First Quarter 2026 Results - ChartMill
1PODD.MI Technical Analysis | Trend, Signals & Chart Patterns | INSULET CORP (BIT:1PODD) - ChartMill
Insulet Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Fidelity Growth Strategies K6 Fund's Insulet Corp(PODD) Holding History - GuruFocus
Insulet in the spotlight: Can earnings calm investor nerves? By Investing.com - Investing.com South Africa
Insulet Corp Azioni (PODD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):